Cargando…

The miRNAs Role in Melanoma and in Its Resistance to Therapy

Melanoma is the less common but the most malignant skin cancer. Since the survival rate of melanoma metastasis is about 10–15%, many different studies have been carried out in order to find a more effective treatment. Although the development of target-based therapies and immunotherapeutic strategie...

Descripción completa

Detalles Bibliográficos
Autores principales: Varrone, Francesca, Caputo, Emilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037367/
https://www.ncbi.nlm.nih.gov/pubmed/32013263
http://dx.doi.org/10.3390/ijms21030878
_version_ 1783500411422900224
author Varrone, Francesca
Caputo, Emilia
author_facet Varrone, Francesca
Caputo, Emilia
author_sort Varrone, Francesca
collection PubMed
description Melanoma is the less common but the most malignant skin cancer. Since the survival rate of melanoma metastasis is about 10–15%, many different studies have been carried out in order to find a more effective treatment. Although the development of target-based therapies and immunotherapeutic strategies has improved chances for patient survival, melanoma treatment still remains a big challenge for oncologists. Here, we collect recent data about the emerging role of melanoma-associated microRNAs (miRNAs) currently available treatments, and their involvement in drug resistance. We also reviewed miRNAs as prognostic factors, because of their chemical stability and resistance to RNase activity, in melanoma progression. Moreover, despite miRNAs being considered small conserved regulators with the limitation of target specificity, we outline the dual role of melanoma-associated miRNAs, as oncogenic and/or tumor suppressive factors, compared to other tumors.
format Online
Article
Text
id pubmed-7037367
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70373672020-03-11 The miRNAs Role in Melanoma and in Its Resistance to Therapy Varrone, Francesca Caputo, Emilia Int J Mol Sci Review Melanoma is the less common but the most malignant skin cancer. Since the survival rate of melanoma metastasis is about 10–15%, many different studies have been carried out in order to find a more effective treatment. Although the development of target-based therapies and immunotherapeutic strategies has improved chances for patient survival, melanoma treatment still remains a big challenge for oncologists. Here, we collect recent data about the emerging role of melanoma-associated microRNAs (miRNAs) currently available treatments, and their involvement in drug resistance. We also reviewed miRNAs as prognostic factors, because of their chemical stability and resistance to RNase activity, in melanoma progression. Moreover, despite miRNAs being considered small conserved regulators with the limitation of target specificity, we outline the dual role of melanoma-associated miRNAs, as oncogenic and/or tumor suppressive factors, compared to other tumors. MDPI 2020-01-29 /pmc/articles/PMC7037367/ /pubmed/32013263 http://dx.doi.org/10.3390/ijms21030878 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Varrone, Francesca
Caputo, Emilia
The miRNAs Role in Melanoma and in Its Resistance to Therapy
title The miRNAs Role in Melanoma and in Its Resistance to Therapy
title_full The miRNAs Role in Melanoma and in Its Resistance to Therapy
title_fullStr The miRNAs Role in Melanoma and in Its Resistance to Therapy
title_full_unstemmed The miRNAs Role in Melanoma and in Its Resistance to Therapy
title_short The miRNAs Role in Melanoma and in Its Resistance to Therapy
title_sort mirnas role in melanoma and in its resistance to therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037367/
https://www.ncbi.nlm.nih.gov/pubmed/32013263
http://dx.doi.org/10.3390/ijms21030878
work_keys_str_mv AT varronefrancesca themirnasroleinmelanomaandinitsresistancetotherapy
AT caputoemilia themirnasroleinmelanomaandinitsresistancetotherapy
AT varronefrancesca mirnasroleinmelanomaandinitsresistancetotherapy
AT caputoemilia mirnasroleinmelanomaandinitsresistancetotherapy